| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1016/J.JACC.2012.01.083 |
| P698 | PubMed publication ID | 22995024 |
| P50 | author | Paola Gargiulo | Q41781643 |
| Gianluigi Savarese | Q43125824 | ||
| P2093 | author name string | Pasquale Perrone-Filardi | |
| Pierluigi Costanzo | |||
| Stefania Paolillo | |||
| Carmen D'Amore | |||
| Caterina Marciano | |||
| Milena Cecere | |||
| Francesca Musella | |||
| Teresa Losco | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q27860606 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| P304 | page(s) | 1192-1201 | |
| P577 | publication date | 2012-09-01 | |
| P1433 | published in | Journal of the American College of Cardiology | Q2984355 |
| P1476 | title | Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials | |
| P478 | volume | 60 |
| Q38834511 | A Contemporary Approach to Pulmonary Arterial Hypertension |
| Q47873724 | A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension |
| Q90185384 | A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension |
| Q41435645 | A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension |
| Q63446871 | Assessment of Right Ventricular Function in the Research Setting: Knowledge Gaps and Pathways Forward. An Official American Thoracic Society Research Statement |
| Q55020470 | Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial. |
| Q38520683 | Biomarkers and prognostic indicators in pulmonary arterial hypertension |
| Q35005853 | Building the case for novel clinical trials in pulmonary arterial hypertension |
| Q47928943 | Cardiopulmonary Exercise Testing in Pulmonary Hypertension. |
| Q55342855 | Change in R wave in lead V1 predicts survival of patients with pulmonary arterial hypertension. |
| Q33788510 | Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension |
| Q50786421 | Classification and diagnosis of pulmonary hypertension. |
| Q91715151 | Clinical outcome and survival in 30 pulmonary hypertension patients with high severity indices and advanced functional class |
| Q61810177 | Clinical trial design and new therapies for pulmonary arterial hypertension |
| Q33788582 | Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges |
| Q38758381 | Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis |
| Q36789240 | Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study |
| Q38721897 | Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH). |
| Q38232339 | Current and advancing treatments for pulmonary arterial hypertension in childhood |
| Q38570060 | Development of macitentan for the treatment of pulmonary arterial hypertension |
| Q57298788 | Distinct loading conditions reveal various patterns of right ventricular adaptation |
| Q64039643 | Early intervention: should we conduct therapeutic trials for mild pulmonary hypertension before onset of symptoms? |
| Q38164816 | Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension |
| Q38403596 | Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. |
| Q98157809 | Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal |
| Q88726723 | Exercise cardiac MRI unmasks right ventricular dysfunction in acute hypoxia and chronic pulmonary arterial hypertension |
| Q26862629 | Exercise training improves physical fitness in patients with pulmonary arterial hypertension: a systematic review and meta-analysis of controlled trials |
| Q33806102 | From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension |
| Q34399959 | Heart rate slopes during 6-min walk test in pulmonary arterial hypertension, other lung diseases, and healthy controls |
| Q38859147 | Hepatoma-derived Growth Factor Predicts Disease Severity and Survival in Pulmonary Arterial Hypertension. |
| Q36721421 | Improvement of Right Ventricular Function in Pulmonary Arterial Hypertension with Disease-Specific Therapy - A Clinical Observational Study |
| Q41669738 | Long-Term Survival of Patients with Pulmonary Arterial Hypertension at a Single Center in Taiwan |
| Q41368070 | MR-proADM Predicts Exercise Capacity and Survival Superior to Other Biomarkers in PH. |
| Q41773926 | Macitentan in pulmonary arterial hypertension: The SERAPHIN trial |
| Q38608883 | Management of patients with pulmonary arterial hypertension due to congenital heart disease: recent advances and future directions |
| Q34614873 | Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials |
| Q50067261 | No, we are not-we keep forgetting the right ventricle |
| Q64092806 | Non-invasive Multimodality Cardiovascular Imaging of the Right Heart and Pulmonary Circulation in Pulmonary Hypertension |
| Q38252605 | Nuclear assessment of right ventricle. |
| Q38542993 | Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists |
| Q34344390 | Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics |
| Q35986352 | Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial |
| Q35986356 | Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. |
| Q44288514 | Prognosis and response to first-line single and combination therapy in pulmonary arterial hypertension |
| Q36882804 | Prognostic value of TAPSE after therapy optimisation in patients with pulmonary arterial hypertension is independent of the haemodynamic effects of therapy |
| Q42008842 | Prognostication in Pulmonary Arterial Hypertension with Submaximal Exercise Testing |
| Q34985436 | Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes |
| Q47862026 | Pulmonary Hypertension and Precision Medicine through the "Omics" Looking Glass |
| Q39317865 | Pulmonary arterial hypertension - progress in understanding the disease and prioritizing strategies for drug development. |
| Q38155079 | Pulmonary arterial hypertension: challenges in translational research and a vision for change |
| Q30583630 | Pulmonary arterial hypertension: the clinical syndrome |
| Q34782622 | Pulmonary hypertension and the right ventricle-thinking outside the box (Third International Right Heart Failure Summit, part 1). |
| Q88716028 | Pulmonary vasodilator therapy in tetralogy of Fallot with pulmonary atresia and major aortopulmonary collaterals: case series and review of literature |
| Q51505943 | Recommendations for utilization of the paracorporeal lung assist device in neonates and young children with pulmonary hypertension. |
| Q48206021 | Right ventricular wave reflection relate to clinical measures in pulmonary arterial hypertension |
| Q41980644 | Riociguat: PATENT-1 Study |
| Q41356862 | Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. |
| Q41625552 | Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial |
| Q38237457 | Six minutes walk test for individuals with schizophrenia |
| Q52659263 | Six-minute walk distance after coronary artery bypass grafting compared with medical therapy in ischaemic cardiomyopathy. |
| Q37680689 | Six-minute walk test in pulmonary arterial hypertension |
| Q38923215 | Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension |
| Q47648153 | The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry |
| Q47791625 | The evolving landscape of combination therapy for pulmonary arterial hypertension |
| Q64980191 | The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry. |
| Q44059611 | To assess exertional breathlessness you must exert the breathless |
| Q26851767 | Treatment goals of pulmonary hypertension |
| Q26823608 | Treatment of idiopathic/hereditary pulmonary arterial hypertension |
| Q36951990 | Treatment of pulmonary arterial hypertension in congenital heart disease in Singapore versus the Netherlands: age exceeds ethnicity in influencing clinical outcome |
| Q64245438 | Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience |
| Q38233856 | Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? |
| Q36810813 | Updating clinical endpoint definitions. |
| Q34865736 | Value of impedance cardiography during 6-minute walk test in pulmonary hypertension |
Search more.